title: [The properties of the epidemic influenza viruses A and B strains circulating in Russia in the 2004-2005 epidemic season].
abstract: The epidemic upsurge of influenza morbidity in Russia in 2004-2005 was caused by the active circulation of influenza A(H3N2) and B viruses. A hundred and sixty-six epidemic strains were studied. All the strains were isolated in the MCK cell culture. Influenza A(H3N2) viruses (n=77) were antigenic variants of the reference A/Fujian/411/ 2002 and A/California/7/2004 strains. Three influenza A(H1N1) viral strains that were antigenic variants of A/New Caledonia/20/99 strains were isolated in sporadic cases. Influenza B virus strains (n=83) were antigenic variants of the reference B/Shanghai/361/02--lineage B/Yamagata/l6/88. In addition, 3 antigenic variants of B/Hong Kong/ 330/2002 (lineage B/Victoria/2/87) strains were isolated. Nine (20%) strains resistant to rimantadine at a concentration of 5 microg/ml were identified. Chromatographic analysis of B/Shanghai/361/02 and BIHong Kong/330/01 viral protein M1 trypsin hydrolysates revealed differences in the profiles of chromatograms of influenza A virus proteins M1. Examination of 121 pair sera from patients revealed an increase in antibodies to influenza A(H3N2) viruses in 10-21% of cases and to influenza B viruses in 20-36% of cases.
authors.forename: V T
authors.initials: VT
authors.lastname: Ivanova
authors.forename: R O
authors.initials: RO
authors.lastname: Rakutina
authors.forename: A N
authors.initials: AN
authors.lastname: Slepushkin
authors.forename: E I
authors.initials: EI
authors.lastname: Burtseva
authors.forename: T A
authors.initials: TA
authors.lastname: Oskerko
authors.forename: E S
authors.initials: ES
authors.lastname: Shevchenko
authors.forename: N V
authors.initials: NV
authors.lastname: Fedorova
authors.forename: L V
authors.initials: LV
authors.lastname: Kordiukova
authors.forename: S V
authors.initials: SV
authors.lastname: Trushakova
authors.forename: E G
authors.initials: EG
authors.lastname: Cherkasov
authors.forename: L N
authors.initials: LN
authors.lastname: Merkulova
authors.forename: E L
authors.initials: EL
authors.lastname: Feodoritova
mesh_terms: D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D000940:Antigenic Variation; D000998:Antiviral Agents / Q000494:pharmacology; D002460:Cell Line; D002645:Chickens; D002851:Chromatography, High Pressure Liquid; D004196:Disease Outbreaks; D024882:Drug Resistance, Viral; D006386:Hemagglutination Tests; D006801:Humans; D006868:Hydrolysis; D053118:Influenza A Virus, H1N1 Subtype / Q000737:chemistry / Q000145:classification / Q000276:immunology; D053122:Influenza A Virus, H3N2 Subtype / Q000737:chemistry / Q000145:classification / Q000276:immunology; D007251:Influenza, Human / Q000453:epidemiology* / Q000821:virology*; D029524:Betainfluenzavirus / Q000145:classification / Q000187:drug effects / Q000276:immunology / Q000302:isolation & purification; D012299:Rimantadine / Q000494:pharmacology; D012426:Russia / Q000453:epidemiology; D014357:Trypsin; D014763:Viral Matrix Proteins / Q000032:analysis / Q000378:metabolism
chemical_list: D000914:Antibodies, Viral; D000998:Antiviral Agents; C488936:M1 protein, Influenza A virus; D014763:Viral Matrix Proteins; D012299:Rimantadine; D014357:Trypsin